Vilin Bio Med Limited Receives National Stock Exchange Trading Approval for Preferential Allotment Shares
Vilin Bio Med Limited announced on April 13, 2026, that the company has secured trading approval from the National Stock Exchange for its equity shares allotted through a preferential allotment.The company confirmed that the National Stock Exchange granted trading approval for a total of 13,00,000 equity shares. These shares have a face value of Rs. 10 each and were allotted on a preferential allotment basis.
The key details of the shares for which trading approval was received are provided below:
| Detail | Value |
|---|---|
| Company Name | Vilin Bio Med Limited |
| NSE Scrip | VILINBIO |
| Total Shares Allotted | 13,00,000 |
| Face Value Per Share | Rs. 10/- |
| Allotment Basis | Preferential Allotment |
The update confirms that the equity shares allotted under the preferential allotment basis are now cleared for trading on the exchange. The company released the notice dated April 13, 2026, with Madhusudhan Yadamakanti Reddy, Managing Director, signing the document.
VILINBIO Stock Price Movement
As of 1:27 PM, shares of Vilin Bio Med Limited are maintaining their ₹37.95 price point in live trading, reflecting a neutral 0.00% movement. The stock is holding stable at this key level, indicating consolidation among traders throughout the ongoing session.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.